Table 3 Cox regression analysis of factors associated with progression-free survival in the two groups

FL group (N = 77)

 Age (< 58 vs. ≥ 58)

0.730(0.381–1.398)

0.342

 Dosage (mg/kg) (7.5 vs. 15)

0.598(0.300–1.193)

0.145

 Complete resection (Yes vs. No)

1.782(0.902–3.520)

0.096

1.949(0.915–4.155)

0.084

 Bevacizumab-primary vs. bevacizumab-secondary

1.216(0.625–2.366)

0.564

 Therapy pattern

0.855(0.563–1.298)

0.462

RT group (N = 78)

 Age (< 58 vs. ≥ 58)

0.748(0.450–1.243)

0.262

 Platinum sensitivity (sensitive vs. resistant)

4.080(2.307–7.218)

< 0.001

4.234(2.217–8.084)

 < 0.001

 Previous lines of chemotherapy (< 3 vs. ≥ 3)

1.426(0.836–2.435)

0.193

 Dosage (mg/kg) (7.5 vs. 15)

0.778(0.419–1.442)

0.425